VEGFA and deep vein thrombosis: Furthermore, the IVT route has been reported to exacerbate the systemic side effects of anti-VEGF agents leading to life threatening systemic cardiovascular as well as cerebrovascular side effects including myocardial infarctions, transient ischemic attacks, deep vein thrombosis, pulmonary embolisms and thrombophlebitis as illustrated in Figure 3C [10].